TRAIL. Successful transduction was confirmed by flow cytometry and cells were subsequently pooled and seeded into a multilayer bioreactor. Once confluent, cells were harvested to form the primary seed stock (PSS). PSS vials underwent further expansion rounds to form a working cell stock (WCC) and subsequent investigational medicinal product (IMP) ready for patient dosing. Trial Design Patients with stage IIIB/IV adenocarcinoma of the lung (EGFR and EML4-ALK negative) will be eligible for enrolment Phase I is a dose de-escalation study ( figure 1A ) where patients will receive pemetrexed and cisplatin on day 1 then 4 × 10 8 MSC-TRAIL cells on day 2 of a 21 day cycle for 3 cycles. Dose limiting toxicities will be recorded. Phase II is a single blinded, randomised, placebo controlled trial consisting of standard chemotherapy and either MSC-TRAIL or placebo (figure 1B). Safety data will be collected and efficacy will be assessed using CT with RECIST (v1.1) criteria at 12 weeks. All patients will be monitored for up to 2 years. Outcomes Phase I primary outcome is safety and tolerability of MSC-TRAIL.
Phase II is tumour response rate by RECIST (v 1.1) criteria at 12 weeks. Conclusion We have produced a viable working bank of genetically modified stem cells, If therapy is effective we will plan to expand into larger phase III trials. Background and Objectives in 2014 the workload relating to surveillance of indeterminate lung nodules was increasing with associated growing need for clinical and administrative resource. A 'virtual' nodule clinic (VNC) was established with clinicians reviewing scan Results and using an electronic proforma to generate a letter to both GP and patient outlining the results and any follow up plans. With each letter the patients are given details of how to arrange a clinic appointment for face-to-face discussion should they wish, as well as an information leaflet about lung nodules. When details of this novel service were presented at the BTS Winter Conference 2015 colleagues questioned the acceptability of this system to patients. Methods as many patients will never be seen in clinic face-toface it was not possible to ask their preference directly. As a surrogate we analysed patient records from each VNC between July 2014 and August 2016 to ascertain which patients had been seen in clinic following a VNC review, and whether that appointment was arranged at the patient's request or by a clinician (for example due to nodule growth). If this was at a patient's request we reviewed outpatient letters to ascertain, where possible, the reason for the review. Results 1591 patient episodes were reviewed. Of these 11 patients requested a face-to-face review. Reasons given included concerns about symptoms, malignancy and stopping follow up too soon. 89 VNC appointments resulted in the clinician requesting an appointment for face-to-face review. Conclusion The VNC is acceptable to patients with less than 1% of patient episodes resulting in a request for a face-to-face review. This compares with 5.6% of patient episodes where the clinician requests an appointment. Reasons given by patients for requesting a review should inform future revision of the patient information leaflet sent with each VNC letter. Introduction Little guidance is available on the optimal framework for surveillance scanning after surgery for lung cancer. At Salford Royal a CT scan is performed on the anniversary of surgery followed by a further 4 years of scans. Previous audit at the hospital has shown that recurrence rates are low and occur mainly within the first 2 years. It may therefore be possible to discharge patients from the clinic earlier than 5 years.
1
Methods All patients undergoing surgical resection at Salford Royal from 2005-2013 were identified. Kaplan-Meier survival curves were then drawn with recurrence of disease, with and without metachronous disease, the event of interest. Estimates of recurrence at each year post-surgery were calculated and the log-rank test used to determine the significance of the differences between stages. Results After exclusions, 211 patients (148 lobectomies; 23 bilobectomies; 20 pneumonectomies; 20 wedge/segmentectomies) were available for analysis. 71 (34%) patients recurred in the 5 years post-surgery; 57 (80%) within the chest. 95% of the 5 year recurrence of stage 1 disease occurred in years 1,2 and 4. 94% and 95% of the 5 year recurrence in years 1-3 for stage 2 and 3 respectively (figure 1). Significant differences in rates of recurrence were found between stages 1 and 2 (p=0.010), and stages 2 and 3 (p=0.032). The rate of metachronous disease for years 1,2,3,4,5 was 1.6%; 0.7%; 0.8%; 2.7%-0.1% (mean 1.2%/year) respectively. 
